

 
 
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
 
Most Trending
CYTK
Cytokinetics Incorpo
$62.25
 Login to see Cytokinetics Incorpo (CYTK)  Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
  Login to see Cytokinetics Incorpo (CYTK)  Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Chart
$56.32 (+10.53%)
$35.14 (+77.15%)
$33.11 (+88.01%)
$56.19 (+10.78%)
CYTK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

 
CYTK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
 Hover over the category for more information
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

CYTK Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
 
 
CYTK Street view is not attractive and have negative views on the near-term outlook
Average key support and resistance price levels.
 Login to display
  Login to displayCYTK Earnings
The TTM reflects 12-month period, providing review of CYTK financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is CYTK current stock price?
What are CYTK stock strengths?
What risks are associated with CYTK stock?
When is CYTK next earnings report?
What is CYTK market cap and volume?
What is CYTK's current Stock IQ?
Should I buy CYTK stock right now?
Is CYTK a Strong Buy right now?
What does a 'Strong Buy' rating mean for CYTK?
What does a 'Strong Sell' rating mean for CYTK?
What factors influence CYTK's Stock IQ?
 
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
CYTK
Cytokinetics Incorpo
Current Price
$62.25
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
 Login to unlock Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
  Login to unlock Cytokinetics Incorpo (CYTK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid  
Chart
$56.32 (+10.53%)
$35.14 (+77.15%)
$33.11 (+88.01%)
$56.19 (+10.78%)
CYTK Analysts Opinion
 
CYTK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
 Hover over the category for more information
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

CYTK Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
 
 
CYTK Street view is not attractive and have negative views on the near-term outlook
CYTK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
 Login to display
  Login to displayCYTK Earnings
The TTM data reflects the most recent 12-month period, providing overview of CYTK financial performance.
CYTK Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
CYTK Latest Analysis
DEADLINE ALERT: Faruqi &. Faruqi LLP Investigates Claims on Behalf of Investors of Cytokinetics. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75000 In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75000 in Cytokinetics between December 27 2023 and May 6...
Wed Oct 29, 2025
 
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CYTK Stock trends
CYTK Stock performance
CYTK Stock analysis
CYTK investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS"). 
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.